Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Palatin Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update

      Palatin Technologies, Inc.

      News provided by

      Palatin Technologies, Inc.

      Nov 17, 2026, 07:30 ET

      Share this article

      Share this article


      Advancing differentiated next-generation MC4R agonists toward first-in-human clinical studies in 2027

      • Lead lipidated, long-acting MC4R-selective peptide advancing through IND-enabling and manufacturing activities, with Phase 1 initiation targeted for the first half of calendar 2027
      • Preclinical findings demonstrate selective and potent MC4R agonism with minimal to no MC1R activity in tested peptide compounds, supporting the potential to substantially reduce or eliminate MC1R-mediated hyperpigmentation
      • Expanding oral MC4R opportunities through next-generation small-molecule development and an oral peptide agonist approach
      • Oral small-molecule MC4R-selective agonist Phase 1 study targeted for the second half of calendar 2027
      • First-quarter R&D investment in MC4R obesity programs more than doubled year over year, reflecting advancement of key preclinical development activities
      • Conference call and webcast scheduled for November 17, 2026 at 11:00 a.m. ET

      PRINCETON, N.J., Nov. 17, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (Nasdaq: PTN), a biopharmaceutical company developing medicines targeting the melanocortin receptor ("MCR") system, today announced financial results for its fiscal 2027 first quarter ended September 30, 2026, and provided an update on its next-generation MC4R-selective obesity development programs and strategic partnerships.

      "MC4R agonism is now a clinically and commercially validated therapeutic approach for rare neuroendocrine obesity disorders, and we believe the next generation of therapies will be defined not only by efficacy, but by meaningful improvements in tolerability, convenience and long-term usability," said Carl Spana, Ph.D., President and Chief Executive Officer of Palatin Technologies. "Our development strategy is specifically designed to address these challenges. We are building on more than two decades of melanocortin research and drug development experience to advance highly selective MC4R agonists with the potential to deliver robust efficacy while substantially reducing, and potentially eliminating, MC1R-mediated hyperpigmentation."

      "Our lead lipidated peptide program represents a particularly compelling opportunity," continued Dr. Spana. "We have demonstrated significant efficacy with once-weekly dosing in preclinical models, and pharmacokinetic findings support the potential for once-weekly or less frequent administration in humans. Equally important, tested compounds in our next-generation peptide series have demonstrated potent MC4R activation without meaningful MC1R activation, an important attribute for developing therapies with improved long-term tolerability. We believe this combination of selectivity, efficacy and sustained activity provides a strong foundation for developing a differentiated therapy for patients who require lifelong treatment."

      "During the quarter, we continued to advance IND-enabling activities with our long-acting peptide while progressing our next-generation oral small-molecule candidates and additionally exploring oral peptide opportunities. We are targeting the initiation of our first Phase 1 study in the first half of 2027, followed by our oral small-molecule program in the second half of 2027. We believe these programs have the potential to establish a new standard for MC4R-targeted treatment of rare obesity disorders."

      MC4R Obesity Program Update

      Palatin is advancing a portfolio of MC4R-selective agonists designed to address hypothalamic obesity ("HO"), Prader-Willi syndrome ("PWS"), Bardet-Biedl syndrome ("BBS") and other rare obesity disorders associated with dysfunction of the melanocortin pathway.

      The Company's strategy focuses on developing therapies with meaningful efficacy, improved gastrointestinal tolerability, reduced or eliminated MC1R-mediated hyperpigmentation, and dosing characteristics suitable for chronic treatment.

      Next-Generation Long-Acting Peptide MC4R Agonists

      Palatin is advancing two complementary MC4R-selective peptide series: lipidated PL2000 and non-lipidated PL1000.

      • The lead lipidated PL2000 development candidate has demonstrated significant reductions in food intake and body weight following once-weekly subcutaneous administration in a diet-induced obese mouse model.
      • Preclinical pharmacokinetic findings support the potential for once-weekly or less frequent dosing in humans.
      • Tested compounds from both peptide series have demonstrated potent MC4R agonist activity without acting as agonists at MC1R, supporting the Company's objective of substantially reducing or potentially eliminating hyperpigmentation associated with MC1R activation.
      • IND-enabling studies and chemistry, manufacturing and controls ("CMC") activities are ongoing for the lead lipidated peptide candidate.
      • Palatin is targeting initiation of a Phase 1 single-ascending-dose/multiple-ascending-dose ("SAD/MAD") clinical study in the first half of calendar 2027, with initial data targeted in the second half of 2027.
      • The Company continues to advance its non-lipidated PL1000 peptide series, including controlled-release formulation development, as an additional approach to long-acting MC4R therapy.

      Next-Generation Oral MC4R Agonists

      Palatin is pursuing oral MC4R-selective therapies through its small-molecule development program and an additional oral peptide agonist approach.

      The oral small-molecule program incorporates data and learnings from earlier development candidates, including PL7737, together with advanced medicinal chemistry, computational drug design, artificial intelligence and machine learning capabilities.

      • Preclinical studies have identified next-generation oral small-molecule candidates with improved potency and MC4R selectivity relative to earlier compounds, together with favorable oral bioavailability.
      • The program is designed to achieve meaningful efficacy with improved tolerability and minimal or no MC1R-mediated hyperpigmentation.
      • Lead candidate selection and optimization activities are ongoing, with IND-enabling development targeted for the first half of calendar 2027.
      • A Phase 1 SAD/MAD study is targeted to initiate in the second half of calendar 2027, with initial clinical data targeted in the first half of 2028.
      • Palatin is also exploring an oral peptide agonist approach as an additional opportunity to expand its MC4R-selective therapeutic portfolio.

      Partnering and Out-Licensing Programs

      Retinal Diseases – Boehringer Ingelheim

      Palatin continues to collaborate with Boehringer Ingelheim on proprietary melanocortin receptor-targeted compounds for retinal diseases, including diabetic retinopathy and diabetic macular edema. Palatin provides research and development support, with approved costs reimbursed by Boehringer Ingelheim.

      The agreement provides for potential future development, regulatory and commercial milestone payments, as well as tiered royalties on net sales of licensed products, if commercialized.

      Palatin recognized approximately $0.4 million in revenue related to the collaboration during the fiscal first quarter.

      PL9643 – Dry Eye Disease

      Palatin's exclusive sublicense agreement with Altanispac Labs covers PL9643 for the treatment of dry eye disease. Altanispac is responsible for future development and commercialization. Palatin remains eligible for additional payments and tiered royalties under the agreement.

      Additional Development and Partnering Opportunities

      Palatin continues to evaluate strategic partnering and out-licensing opportunities for its bremelanotide co-administration program in obesity, PL8177 or other novel MC1R agonist in ulcerative colitis and its melanocortin receptor agonist program for diabetic nephropathy.

      These programs provide opportunities to advance additional assets through strategic collaborations while maintaining Palatin's primary development focus on next-generation MC4R therapies for rare obesity disorders.

      Fiscal 2027 First Quarter Ended September 30, 2026 Financial Results Revenue

      For the fiscal first quarter ended September 30, 2026, Palatin recognized approximately $0.4 million in collaboration and license revenue, compared with approximately $8.8 million for the comparable prior-year period.

      Revenue for the current quarter was attributable to research and development services performed under the Boehringer Ingelheim collaboration. The prior-year period included upfront and milestone revenue associated with that agreement.

      Research and Development Expenses

      Research and development expenses were approximately $3.4 million, compared with approximately $2.5 million for the comparable prior-year period.

      R&D spending directly related to the Company's MC4R obesity programs increased to approximately $2.1 million from approximately $1.0 million in the prior-year period. The increase was primarily attributable to IND-enabling preclinical studies and related activities for the long-acting MC4R peptide program and lead candidate optimization activities for the oral small-molecule program.

      General and Administrative Expenses

      General and administrative expenses were approximately $2.1 million, compared with approximately $1.7 million for the comparable prior-year period. The increase was primarily attributable to higher stock-based compensation expenses and professional fees.

      Net Loss

      Palatin reported a net loss of approximately $5.1 million, or $1.29 per basic and diluted common share, for the fiscal first quarter ended September 30, 2026.

      Cash Flows and Cash Position

      Net cash used in operating activities was approximately $3.7 million for the fiscal first quarter ended September 30, 2026, compared with approximately $1.6 million for the comparable prior-year period.

      As of September 30, 2026, Palatin had cash and cash equivalents of approximately $3.7 million, compared with approximately $7.5 million as of June 30, 2026.

      The Company intends to pursue additional financing and strategic opportunities to support continued advancement of its development programs. Additional funding will be required to execute its planned development activities and fund operations. Accordingly, substantial doubt exists regarding the Company's ability to continue as a going concern for one year following issuance of its financial statements.

      Conference Call and Webcast

      Palatin will host a conference call and audio webcast on November 17, 2026, at 11:00 a.m. Eastern Time, to discuss its fiscal first-quarter financial results and provide an update on corporate and development activities.

      To listen to the live conference call, dial 1-888-506-0062 (US) or 1-973-528-0011 (International), Participant Access Code: 336522. The audio webcast and replay can be accessed by logging on to the "Investor-Webcasts" section of Palatin's website at http://www.palatin.com. A telephone and audio webcast replay will be available one hour after the completion of the call. To access the telephone replay, dial 1-877-481-4010 (US) or 1-919-882-2331 (International), Replay Passcode 54837. The webcast and telephone replay will be available through December 1, 2026.

      About Palatin Technologies

      Palatin Technologies, Inc. is a biopharmaceutical company developing medicines targeting the melanocortin receptor system. Palatin's principal strategic development focus is advancing next-generation MC4R-selective agonists for rare neuroendocrine obesity disorders, including hypothalamic obesity, Prader-Willi syndrome and Bardet-Biedl syndrome. The Company is developing long-acting injectable peptide agonists, oral small-molecule agonists and an oral peptide agonist approach, with the objective of delivering differentiated efficacy, tolerability and dosing profiles suitable for long-term treatment. Palatin also utilizes collaborations, licensing arrangements and strategic partnerships to advance other melanocortin-based programs. For more information, visit www.palatin.com.

      Forward-Looking Statements

      Statements in this press release that are not historical facts, including statements regarding Palatin's product candidates, potential clinical benefits, efficacy, tolerability, receptor selectivity, dosing frequency, development programs, regulatory submissions, clinical trial initiation and results, collaborations, financing plans and future operations, are forward-looking statements within the meaning of applicable federal securities laws. These statements involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Such risks include the results of preclinical and clinical studies, regulatory decisions, manufacturing and development timelines, Palatin's ability to obtain sufficient financing, the performance of collaborators and licensees, competing therapies, market conditions and other risks described in Palatin's filings with the Securities and Exchange Commission. Palatin undertakes no obligation to update forward-looking statements except as required by law.


      PALATIN TECHNOLOGIES, INC


      and Subsidiary


      Consolidated Statements of Operations


      (unaudited)









      Three Months Ended September 30,




      2026


      2025









      REVENUES






      Collaboration and license

      $                    361,802


      $                8,847,550









      OPERATING EXPENSES






      Research and development

      3,383,743


      2,525,766



      General and administrative

      2,080,414


      1,660,731



      Total operating expenses

      5,464,157


      4,186,497









      (Loss) Income from operations

      (5,102,355)


      4,661,053









      OTHER INCOME (EXPENSE)






      Investment income

      46,534


      18,483



      Interest expense

      (1,690)


      (2,002)



      Total other (expense) income, net

      44,844


      16,481









      NET (LOSS) INCOME

      $               (5,057,511)


      $                4,677,534









      Basic net (loss) income per common share

      $                        (1.29)


      $                         4.81









      Diluted net (loss) income per common share

      $                        (1.29)


      $                         4.26









      Weighted average number of common shares
      outstanding used in computing basic net (loss)
      income per common share

      3,922,464


      971,650









      Weighted average number of common shares
      outstanding used in computing diluted net (loss)
      income per common share

      3,922,464


      1,098,490



      PALATIN TECHNOLOGIES, INC


      and Subsidiary


      Consolidated Balance Sheets


      (unaudited)








      September 30, 2026


      June 30, 2026


      ASSETS





      Current assets:





      Cash and cash equivalents

      $                  3,740,424


      $      7,492,014


      Accounts receivable

      361,802


      300,770


      Prepaid expenses and other current assets

      337,765


      371,703


      Total current assets

      4,439,991


      8,164,487







      Property and equipment, net

      101,112


      118,064


      Right-of-use assets - operating leases

      155,448


      219,677


      Other assets

      21,626


      21,626


      Total assets

      $                  4,718,177


      $      8,523,854







      LIABILITIES AND STOCKHOLDERS' EQUITY





      Current liabilities:





      Accounts payable

      $                  1,360,530


      $      1,109,552


      Accrued expenses

      1,171,975


      504,158


      Short-term operating lease liabilities

      126,661


      158,263


      Total current liabilities

      2,659,166


      1,771,973







      Long-term operating lease liabilities

      32,932


      65,416


      Total liabilities

      2,692,098


      1,837,389







      Stockholders' equity:





      Preferred stock of $0.01 par value – authorized 10,000,000 shares: shares





      issued and outstanding designated as follows:





      Series A Convertible: authorized 4,030 shares as of September 30, 2026: issued





      and outstanding 4,030 shares as of September 30, 2026 and June 30, 2026

      40


      40


      Series D Convertible: authorized 3,400 shares as of September 30, 2026: issued





      and outstanding 3,400 shares as of September 30, 2026 and June 30, 2026

      34


      34


      Common stock of $0.01 par value – authorized 300,000,000 shares:





      issued and outstanding 1,780,939 shares as of September 30, 2026 and 1,779,275
      shares as of June 30, 2026

      17,809


      17,793


      Additional paid-in capital

      474,517,501


      474,120,392


      Accumulated deficit

      (472,509,305)


      (467,451,794)


      Total stockholders' equity

      2,026,079


      6,686,465


      Total liabilities and stockholders' equity

      $                  4,718,177


      $      8,523,854

















      BS Check

      $                                -


      $                   -


      Working Capital

      1,780,825


      6,392,514

      SOURCE Palatin Technologies, Inc.

      Modal title

      Also from this source

      Palatin Technologies Presents Compelling Preclinical Data on Next-Generation MC4R-Selective Peptide Agonists at ObesityWeek® 2026

      Palatin Technologies Presents Compelling Preclinical Data on Next-Generation MC4R-Selective Peptide Agonists at ObesityWeek® 2026

      Palatin Technologies, Inc. (Nasdaq: PTN), a biopharmaceutical company developing differentiated, next-generation melanocortin receptor agonists,...

      Palatin to Report First Quarter Fiscal Year 2027 Results

      Palatin to Report First Quarter Fiscal Year 2027 Results

      Palatin Technologies, Inc. (Nasdaq: PTN) will announce its first quarter fiscal year 2027 operating results on Tuesday, November 17, 2026, before the ...

      More Releases From This Source

      Explore

      Biotechnology

      Biotechnology

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Pharmaceuticals

      Pharmaceuticals

      Health Care & Hospitals

      Health Care & Hospitals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.